




PHARMACEUTICAL 2023

Imunon Inc.
Rank 253 of 446





PHARMACEUTICAL 2023

Imunon Inc.
Rank 253 of 446



The relative strengths and weaknesses of Imunon Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Imunon Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Imunon Inc. is the variable Net Income, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 50%, being 6.5% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	37,155
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,037
Liabilities, Non-Current	0
Other Assets	6,273
Other Compr. Net Income	26
Other Expenses	-1,567
Other Liabilities	4,611
Other Net Income	-12,544
Other Revenues	500
Property and Equipment	548
Research and Development	11,734
Selling, General and Administrative Expense	13,688

Output Variable	Value in 1000 USD
Assets	43,976
Liabilities	14,648
Expenses	23,855
Revenues	500
Stockholders Equity	29,328
Net Income	-35,898
Comprehensive Net Income	-35,885
Economic Capital Ratio	50%